Hendley & Co. Inc. cut its holdings in Johnson & Johnson (NYSE:JNJ) by 1.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 59,903 shares of the company’s stock after selling 1,069 shares during the quarter. Johnson & Johnson makes up about 4.3% of Hendley & Co. Inc.’s investment portfolio, making the stock its 5th largest position. Hendley & Co. Inc.’s holdings in Johnson & Johnson were worth $7,788,000 at the end of the most recent quarter.
A number of other large investors have also added to or reduced their stakes in JNJ. Fox Run Management L.L.C. raised its position in shares of Johnson & Johnson by 231.6% in the 3rd quarter. Fox Run Management L.L.C. now owns 6,300 shares of the company’s stock valued at $819,000 after purchasing an additional 4,400 shares during the last quarter. Adviser Investments LLC raised its position in shares of Johnson & Johnson by 11.5% in the 3rd quarter. Adviser Investments LLC now owns 28,068 shares of the company’s stock valued at $3,649,000 after purchasing an additional 2,890 shares during the last quarter. Bartlett & Co. LLC raised its position in shares of Johnson & Johnson by 3.5% in the 3rd quarter. Bartlett & Co. LLC now owns 196,371 shares of the company’s stock valued at $25,530,000 after purchasing an additional 6,595 shares during the last quarter. River & Mercantile Asset Management LLP raised its position in shares of Johnson & Johnson by 27.1% in the 3rd quarter. River & Mercantile Asset Management LLP now owns 29,633 shares of the company’s stock valued at $3,852,000 after purchasing an additional 6,320 shares during the last quarter. Finally, CAPROCK Group Inc. raised its position in shares of Johnson & Johnson by 0.9% in the 3rd quarter. CAPROCK Group Inc. now owns 47,119 shares of the company’s stock valued at $6,126,000 after purchasing an additional 424 shares during the last quarter. 65.70% of the stock is owned by institutional investors.
Johnson & Johnson (NYSE:JNJ) opened at $145.76 on Friday. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $391,590.00, a price-to-earnings ratio of 25.31, a price-to-earnings-growth ratio of 2.73 and a beta of 0.80. Johnson & Johnson has a fifty-two week low of $110.76 and a fifty-two week high of $146.42.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The business had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. During the same quarter in the previous year, the firm earned $1.68 EPS. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. equities research analysts forecast that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, February 26th. This represents a $3.36 annualized dividend and a dividend yield of 2.31%. Johnson & Johnson’s dividend payout ratio is presently 58.33%.
Several equities analysts recently weighed in on JNJ shares. Piper Jaffray Companies reiterated a “hold” rating and issued a $120.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 4th. Vetr downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 price target on the stock. in a report on Monday, September 18th. Stifel Nicolaus increased their price target on shares of Johnson & Johnson from $140.00 to $142.00 and gave the stock a “hold” rating in a report on Wednesday, October 18th. Wells Fargo & Co upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $140.00 to $149.00 in a report on Monday, October 9th. Finally, JPMorgan Chase & Co. cut shares of Johnson & Johnson from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 2nd. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $145.94.
TRADEMARK VIOLATION NOTICE: This story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/14/hendley-co-inc-decreases-holdings-in-johnson-johnson-jnj.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.